TU Darmstadt / ULB / TUprints

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

Bensinger, Dennis ; Stubba, Daniel ; Cremer, Anjali ; Kohl, Vanessa ; Waßmer, Theresa ; Stuckert, Johanna ; Engemann, Victoria ; Stegmaier, Kimberly ; Schmitz, Katja ; Schmidt, Boris (2019)
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.
In: Journal of Medicinal Chemistry, 62 (5)
doi: 10.25534/tuprints-00009651
Article, Primary publication

[img]
Preview
Text
Schmidt-Boris-Virtual Screening Identifies.pdf
Copyright Information: CC BY-NC 4.0 International - Creative Commons, Attribution NonCommercial.

Download (2MB) | Preview
Item Type: Article
Type of entry: Primary publication
Title: Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations
Language: English
Date: 2019
Publisher: American Chemical Society
Journal or Publication Title: Journal of Medicinal Chemistry
Volume of the journal: 62
Issue Number: 5
DOI: 10.25534/tuprints-00009651
Corresponding Links:
Abstract:

The use of covalent irreversible binding inhibitors is an established concept for drug development. Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed. Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia. A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chemically reactive groups. Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds. Lead compound 4b (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compounds in recent clinical trials and overcomes drug-resistant mutations.

URN: urn:nbn:de:tuda-tuprints-96515
Classification DDC: 500 Science and mathematics > 540 Chemistry
Divisions: 07 Department of Chemistry > Clemens-Schöpf-Institut > Organ Chemistry
Date Deposited: 06 Dec 2019 07:32
Last Modified: 10 Dec 2019 13:10
URI: https://tuprints.ulb.tu-darmstadt.de/id/eprint/9651
PPN:
Export:
Actions (login required)
View Item View Item